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Introduction
In Regenerative Medicine one or more regenerative fac-
tors can be applied inside a cartilagine or bone defect to
obtain a more rapid and complete healing. Bone Mar-
row Cells (BMC) added to Platelet-Rich Plasma (PRP)
contain stromal cells which can differentiate in osteo-
clasts and osteoblasts and can be able to form osteo-
genic tissue and to repair bone defects secondary to
degenerative processes.
Case report
We report on a 15-year-old boy, followed at our Depart-
ment, affected by JIA since he was 2 years old. He pre-
sented a systemic form, evolved into a polyarticular
form, treated with steroids and immunosuppressor
drugs. The patient had a good response to treatment
with Enbrel, which he is still taking. In January 2009, he
presented right hip pain and functional limitation. In
July 2009 he underwent MRI of the hip joints which
showed osteonecrosis in chondral/subchondral regions
at the superior-external convexity of the right femoral
head. We recommended deambulation with crutches
and no weight bearing. Because of the persistence of
joint symptoms, in July we implanted BMC plus PRP in
the osteonecrotic region with improvement of pain and
mobilization. In October 2010, he presented left hip
pain. MRI showed focal osteonecrosis in subchodral
region of left femoral head convexity. For this reason,
we made a second BMC plus PRP implantation in the
left hip. At present, patient walks autonomously, without
joint pain and with improved hip movements; he is still
on Enbrel and NSAIDs.
Conclusions
To the best of our knowledge, there are no literature
data on the use of BMC plus PRP in pediatric patients
affected by JIA. Considering the obvious limitations of
our single case report, we observed a good short-term
outcome. Therefore, follow-up is essential to check if
BMC plus PRP implantation represents only a palliative
care to delay surgical treatment or if it is a valid alterna-
tive to traditional orthopedic surgery.
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